{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:26:58Z","timestamp":1793309218680,"version":"4.5.0"},"reference-count":13,"publisher":"Japan Surgical Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Surg Case Rep"],"published-print":{"date-parts":[[2026]]},"DOI":"10.70352\/scrj.cr.26-0344","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:11:24Z","timestamp":1789596684000},"page":"n\/a","source":"Crossref","is-referenced-by-count":2,"title":["Nodular Regenerative Hyperplasia Suggested by Noninvasive Findings during Adjuvant Trastuzumab Emtansine Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer"],"prefix":"10.70352","volume":"12","author":[{"given":"Hideyuki","family":"Yamada","sequence":"first","affiliation":[{"name":"Chiba Cancer Center, Chiba, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikiya","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Chiba Cancer Center, Chiba, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouko","family":"Hayama","sequence":"additional","affiliation":[{"name":"Chiba Cancer Center, Chiba, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reina","family":"Okuya","sequence":"additional","affiliation":[{"name":"Chiba Cancer Center, Chiba, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Oshida","sequence":"additional","affiliation":[{"name":"Cosmos Clinic, Ichihara, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Oshida","sequence":"additional","affiliation":[{"name":"Cosmos Clinic, Ichihara, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Chiba Foundation for Health Promotion & Disease Prevention, Chiba, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Ito","sequence":"additional","affiliation":[{"name":"Ito Shinkemigawa Clinic, Chiba, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Ota","sequence":"additional","affiliation":[{"name":"Department of Surgery, Sanmu Medical Center, Chiba, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atushi","family":"Yoshii","sequence":"additional","affiliation":[{"name":"Tokyo City Clinic Ryogoku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahito","family":"Masuda","sequence":"additional","affiliation":[{"name":"Masuda Clinic, Funabashi, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinobu","family":"Araki","sequence":"additional","affiliation":[{"name":"Chiba Cancer Center, Chiba, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Sudo","sequence":"additional","affiliation":[{"name":"Chiba Cancer Center, Chiba, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"51119","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783\u201391.","DOI":"10.1056\/NEJMoa1209124"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019; 380: 617\u201328.","DOI":"10.1056\/NEJMoa1814017"},{"key":"3","unstructured":"3) National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 5.0. Bethesda, MD: National Cancer Institute; 2017."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Krop IE, Kim SB, Gonz\u00e1lez-Mart\u00edn A, et al. Trastuzumab emtansine versus treatment of physician\u2019s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 689\u201399.","DOI":"10.1016\/S1470-2045(14)70178-0"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Reshamwala PA, Kleiner DE, Heller T. Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology 2006; 44: 7\u201314.","DOI":"10.1002\/hep.21258"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Di\u00e9ras V, Harbeck N, Budd GT, et al. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis. J Clin Oncol 2014; 32: 2750\u20137.","DOI":"10.1200\/JCO.2013.54.4999"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Force J, Saxena R, Schneider BP, et al. Nodular regenerative hyperplasia after treatment with trastuzumab emtansine. J Clin Oncol 2016; 34: e9\u201312.","DOI":"10.1200\/JCO.2013.49.8543"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Prochaska LH, Damjanov I, Ash RM, et al. Trastuzumab emtansine associated nodular regenerative hyperplasia: a case report and review of literature. Cancer Treat Commun 2016; 5: 26\u201330.","DOI":"10.1016\/j.ctrc.2015.11.008"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Lepelley M, Allouchery M, Long J, et al. Nodular regenerative hyperplasia induced by trastuzumab emtansine: role of emtansine? Ann Hepatol 2018; 17: 1067\u201371.","DOI":"10.5604\/01.3001.0012.7207"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Benguerfi S, Di\u00e9ras V, Campone M, et al. Regenerative nodular hyperplasia after T-DM1: consequences from sinusoidal endothelium damages. Acta Oncol 2020; 59: 306\u20139.","DOI":"10.1080\/0284186X.2019.1670860"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Hassan C, Correal F, V\u00e9zina G, et al. Safety of trastuzumab after trastuzumab emtansine-induced nodular regenerative hyperplasia: a case report. J Oncol Pharm Pract 2020; 26: 1780\u20134.","DOI":"10.1177\/1078155220910252"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Ozaki K, Tanahashi Y, Goshima S. Gadoxetic acid-enhanced MRI in hepatocellular carcinoma: a comprehensive review of diagnostic, surveillance, and treatment response prediction and assessment. Jpn J Radiol 2026; 44: 2\u201323.","DOI":"10.1007\/s11604-025-01870-x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Yamamoto A, Matsuda H, Hiramatsu K, et al. A case of idiopathic portal hypertension accompanying multiple hepatic nodular regenerative hyperplasia in a patient with systemic sclerosis. Clin J Gastroenterol 2021; 14: 820\u20136.","DOI":"10.1007\/s12328-021-01348-z"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/12\/1\/12_cr.26-0344\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:24:38Z","timestamp":1789791878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/12\/1\/12_cr.26-0344\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.70352\/scrj.cr.26-0344","relation":{},"ISSN":["2198-7793"],"issn-type":[{"value":"2198-7793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"cr.26-0344"}}